Publication at Second Faculty of Medicine |
2013
Abstract
Lixisenatid a new receptor agonist of the glucagon-like peptide 1 (GLP-1). Apply once a day subcutaneously, basic dose is 20 mg.
Lixisenatid has a favorable safety and efficacy ratio significantly affects especially postprandial glycemia, as monotherapy, in combination with metformin and other oral antidiabetic agents effectively reduces glycated hemoglobin values. As appears very advantageous combination with basal insulin analogue.